Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Represents Kinnate Biopharma in $276 Million IPO
On December 7, 2020, Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of its initial public offering, raising $276 million. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol “KNTE.” All shares were offered by Kinnate.
Client Highlights
Wilson Sonsini Advises Lumentum on $5.7 Billion Acquisition of Coherent
On January 19, 2021, Lumentum Holdings Inc., a designer and manufacturer of innovative optical and photonic products, and Coherent, Inc., a global supplier of industrial and fiber laser solutions, announced a definitive agreement under which Lumentum will acquire Coherent in a cash and stock transaction valued at $5.7 billion. Wilson Sonsini Goodrich & Rosati is advising Lumentum on the transaction.
Client Highlights
Firm Advises Multiverse on $44 Million Series B Fundraise
On January 19, 2021, Multiverse (formerly known as WhiteHat), a UK start-up that works with organizations to develop apprenticeships and helps source promising, diverse candidates to fill those roles, announced a $44 million Series B funding round. The funding will be used to spearhead a move into the U.S. market after picking up over 300 clients in the UK and thousands of apprentices. Wilson Sonsini Goodrich & Rosati advised Multiverse on the fundraise, in collaboration with Taylor Wessing.
The round was led by General Catalyst, with GV (formerly known as Google Ventures), Audacious Ventures, Latitude, and SemperVirens also participating. In addition, Index Ventures and Lightspeed Venture Partners, who first invested in the company in its $16 million Series A in 2020, participated in the round.
The Wilson Sonsini team advising Multiverse includes Michael Labriola, Daniel Glazer, Amanda Pollard, and Alex Moffitt.
The round was led by General Catalyst, with GV (formerly known as Google Ventures), Audacious Ventures, Latitude, and SemperVirens also participating. In addition, Index Ventures and Lightspeed Venture Partners, who first invested in the company in its $16 million Series A in 2020, participated in the round.
The Wilson Sonsini team advising Multiverse includes Michael Labriola, Daniel Glazer, Amanda Pollard, and Alex Moffitt.
Client Highlights
Wilson Sonsini Advises AuraVax on Exclusive License Agreement with Massachusetts General Hospital
On January 13, 2021, AuraVax Therapeutics Inc., a biotech company developing novel vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists led by Mei X. Wu, Ph.D., of the Wellman Center for Photomedicine at MGH. Research related to this technology was published in Science in February 2020.
Client Highlights
Wilson Sonsini Advises Earli on IP Matters Related to $40 Million Series A
On January 12, 2021, bioengineering firm Earli, which developed in stealth a new platform technology that will allow clinicians to exactly locate early cancers so they can be treated, announced that it has raised $40 million in Series A funding. The financing was led by Khosla Ventures, along with Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital, and top individuals including Midas List investors Jim Breyer/Breyer Capital and Rahul Mehta, Goldman Sachs’s former CFO and CIO R. Martin Chavez, and biomedical device entrepreneur Shlomo Ben-Haim. Wilson Sonsini Goodrich & Rosati advised Earli on IP matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Blend on $300 Million Series G Financing
On January 13, 2021, Blend, a leader in digital lending solutions, announced a $300 million Series G funding round led by Coatue and Tiger Global, nearly doubling its valuation to $3.3 billion in just five months. Wilson Sonsini Goodrich & Rosati advised Blend on the fundraise.
The Entrepreneurs Report - Q3 2020
In this issue, we've compiled a range of data on venture financing transactions in which Wilson Sonsini was involved during Q3 2020, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. In addition, the publication features an interview that Boston corporate partner Mark Solakian conducted with Dr. Wasim Malik of Iaso Ventures, the nation’s first sector-focused neuroscience and mental health venture capital firm, as well as data from Beauhurst on UK equity investment in Q3 2020.
